These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 11571449

  • 1. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.
    Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A, Baird C, Iurlano K, Mazariegos G, Cooperstone B, Holt DW, Zeevi A, Fung JJ, Reyes J.
    Transplantation; 2001 Sep 15; 72(5):851-5. PubMed ID: 11571449
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

  • 3. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus.
    McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS.
    Liver Transpl; 2001 Aug 15; 7(8):701-8. PubMed ID: 11510015
    [Abstract] [Full Text] [Related]

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.
    Pediatr Transplant; 1999 Feb 15; 3(1):22-6. PubMed ID: 10359027
    [Abstract] [Full Text] [Related]

  • 6. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 7. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Nov 15; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 8. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 9. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
    Gralla J, Wiseman AC.
    Transplantation; 2009 Jun 15; 87(11):1712-9. PubMed ID: 19502965
    [Abstract] [Full Text] [Related]

  • 10. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 11. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R.
    Liver Transpl; 2000 Nov 27; 6(6):734-40. PubMed ID: 11084060
    [Abstract] [Full Text] [Related]

  • 12. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb 27; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 13. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA, International Sirolimus Study Group.
    Transplantation; 2009 Oct 27; 88(8):1010-8. PubMed ID: 19855247
    [Abstract] [Full Text] [Related]

  • 14. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
    Fukushima D, Sato K, Kawagishi N, Ohuchi N, Satomi S.
    Transplantation; 2015 Jan 15; 99(1):114-9. PubMed ID: 24846306
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus in pediatric liver transplantation: a single-center experience.
    Gibelli NE, Tannuri U, Pinho-Apezzato ML, Tannuri AC, Maksoud-Filho JG, Andrade WC, Velhote MC, Santos MM, Ayoub AA, Marques da Silva M.
    Transplant Proc; 2009 Apr 15; 41(3):901-3. PubMed ID: 19376384
    [Abstract] [Full Text] [Related]

  • 17. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J.
    Transplantation; 1998 Oct 27; 66(8):1047-52. PubMed ID: 9808490
    [Abstract] [Full Text] [Related]

  • 18. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE.
    Transplantation; 1999 Dec 27; 68(12):1851-4. PubMed ID: 10628763
    [Abstract] [Full Text] [Related]

  • 19. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J, Ríos M G, Vignolo A P, Pinochet V C, Schultz M, Humeres A R, Delucchi A, Rius A M, Hepp K J.
    Rev Med Chil; 2008 May 27; 136(5):631-6. PubMed ID: 18769812
    [Abstract] [Full Text] [Related]

  • 20. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.
    Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH, Kumar A.
    Transplantation; 2005 Sep 27; 80(6):807-14. PubMed ID: 16210969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.